2025-06-10-Jefferies-视频回放_竞争激烈的MRD领域中的支付方动态_8页_831kb

Equity Research Summary: Life Science Tools & Diagnostics

This report, dated June 10, 2025, from Jefferies Equity Research, focuses on the US life science tools and diagnostics sector, with particular emphasis on payer dynamics in the competitive minimal residual disease (MRD) diagnostic and testing space. The analysis is based on a conference call with Matthew Loftus, VP of Product Development from a PBM contracted by Blue Cross Blue Shield. Key discussions center on how payers are incorporating MRD tests into CMC/commercial coverage plans, though detailed outcomes are not provided here.

Company-Specific Valuations and Risks

• Tempest Therapeutics: Recommended buy price target of $15, blending discounted cash flow (DCF) and probability-adjusted earnings per share (EPS) analyses. Key risks include efficacy concerns, toxicity issues, and competitive pressures.

• UnitedHealth Group Incorporated: Buy price target of $400, based on a 14.5x multiple of projected 2026 EPS. Risks include utilization and acuity rebound trajectories, potential unemployment spikes impacting enrollment, slower growth in capitated lives, Optum earnings deceleration, political factors, and regulatory changes.

Rating System

• Buy: Expected total return (price appreciation + yield) of 15% or more for securities generally priced above $10; Buy ratings are stricter for low-pricing stocks.
• Hold: Expected return between -10% and +15% or other specified ranges depending on stock price.
• Underperform: Expected return of -10% or less.
• These ratings incorporate analyses like DCF, EPS, P/E ratios, and revenue streams.

Key Disclosures and Analyst Certifications

All analysts certifying that their views reflect personal opinions and that compensation is not tied to recommendations. A detailed disclosure section covers potential conflicts of interest, with Jefferies expected to receive compensation from investment banking services for covered companies like Tempest Therapeutics and UnitedHealth. The report notes general legal disclaimers, including risks to investments, potential currency effects, and the non-guaranteed nature of past performance.

Broader Report Notes

• Analysts who initiated coverage or changed ratings for these companies.
• Distribution rules and limitations ensure the report is confined to Jefferies clients only.

For detailed financial data and historical rating changes, refer to the full report attachments.